These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A primer on topical antibiotics for the skin and eyes. Noah S J Drugs Dermatol; 2008 Apr; 7(4):409-15. PubMed ID: 18459527 [TBL] [Abstract][Full Text] [Related]
6. Safety of moxifloxacin as shown in animal and in vitro studies. McGee DH; Holt WF; Kastner PR; Rice RL Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310 [TBL] [Abstract][Full Text] [Related]
7. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. Kuehne JJ; Yu AL; Holland GN; Ramaswamy A; Taban R; Mondino BJ; Yu F; Rayner SA; Giese MJ Am J Ophthalmol; 2004 Oct; 138(4):547-53. PubMed ID: 15488779 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Stroman DW; Dajcs JJ; Cupp GA; Schlech BA Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308 [TBL] [Abstract][Full Text] [Related]
11. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309 [TBL] [Abstract][Full Text] [Related]
12. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. Koch HR; Kulus SC; Roessler M; Ropo A; Geldsetzer K J Cataract Refract Surg; 2005 Jul; 31(7):1377-85. PubMed ID: 16105610 [TBL] [Abstract][Full Text] [Related]
13. Potential of old-generation antibiotics to address current need for new antibiotics. Falagas ME; Grammatikos AP; Michalopoulos A Expert Rev Anti Infect Ther; 2008 Oct; 6(5):593-600. PubMed ID: 18847400 [TBL] [Abstract][Full Text] [Related]
14. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. Hariprasad SM; Shah GK; Chi J; Prince RA J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929 [TBL] [Abstract][Full Text] [Related]
16. Antibacterial agents for ocular therapeutics. Kern TJ Vet Clin North Am Small Anim Pract; 2004 May; 34(3):655-68. PubMed ID: 15110977 [TBL] [Abstract][Full Text] [Related]
18. Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea. Kaye SB; Neal T; Nicholson S; Szkurlat J; Bamber S; Baddon AC; Anderson S; Seddon K; Dwyer N; Lovering AM; Smith G Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3176-84. PubMed ID: 19218614 [TBL] [Abstract][Full Text] [Related]
19. Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye. Jain D; Carvalho E; Banthia AK; Banerjee R Drug Dev Ind Pharm; 2011 Feb; 37(2):167-77. PubMed ID: 21073319 [TBL] [Abstract][Full Text] [Related]